Drug Trial Radar · NCT03946670
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
127
Actual
Start
Jun 4, 2019
Primary completion
Apr 26, 2022
Study completion Jul 15, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II was a multicenter, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or decitabine) in adult subjects with IPSS-R intermediate, high or very high risk myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplant (HSCT) or intensive chemotherapy.
Conditions
- Myelodysplastic Syndromes
Interventions
MBG453Drug
MBG453 is being administered i.v.
PlaceboDrug
Placebo is being administered i.v.
Hypomethylating agentsDrug
Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Remission (CR) RateTime frame: average of 7 months
- Progression Free Survival (PFS)Time frame: approx. 32 months
Locations
48 sites in 17 countries. Site status is shown where the registry gives one.
City Of Hope National Med Center
Duarte, California
City of Hope National Medical Center Medical Oncology & Therapeutic
Duarte, California
Yale University School Of Medicine
New Haven, Connecticut
Dana Farber Cancer Institute
Boston, Massachusetts
The Cancer Institute of New Jersey
New Brunswick, New Jersey
Ohio State Comprehensive Cancer Center James Cancer Hospital
Columbus, Ohio
Mary Crowley Cancer Research
Dallas, Texas
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Brasschaat, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Leipzig, Saxony, Germany
Novartis Investigative Site
Alexandroupoli, Greece
Novartis Investigative Site
Larissa, Greece
Novartis Investigative Site
Pátrai, Greece
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Nyíregyháza, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Reggio Calabria, RC, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Gifu, Japan
Novartis Investigative Site
Osaka, Japan
Novartis Investigative Site
Fukuoka, Fukuoka, Japan
Novartis Investigative Site
Fukushima, Fukushima, Japan
Novartis Investigative Site
Isehara, Kanagawa, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, Japan
Novartis Investigative Site
Sendai, Miyagi, Japan
Novartis Investigative Site
Nagasaki, Nagasaki, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Málaga, Spain
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.